Lung Malignancies in HIV Infection

Abstract

Pulmonary malignancies are a major source of morbidity and mortality in HIV-infected persons. Non–AIDS-defining lung cancers (mostly non-small cell lung cancers) are now a leading cause of cancer death among HIV-infected persons. HIV-associated factors appear to affect the risk of lung cancer and may adversely impact cancer treatment and outcomes. HIV infection also may modify the potential harms and benefits of lung cancer screening with computed tomography. AIDS-defining lung malignancies include pulmonary Kaposi sarcoma and pulmonary lymphoma, both of which are less prevalent with widespread adoption of antiretroviral therapy.

Keywords

HIV - lung - non-small cell lung cancer - AIDS-related Kaposi sarcoma - non-Hodgkin lymphoma

• References

• 1 Hakimian R, Fang H, Thomas L, Edelman MJ. Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol 2007; 2 (4) 268-272
• 2 Engels EA, Pfeiffer RM, Goedert JJ , et al; HIV/AIDS Cancer Match Study. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20 (12) 1645-1654
• 3 Levine AM. Non-Hodgkin's lymphomas and other malignancies in the acquired immune deficiency syndrome. Semin Oncol 1987; 14 (2) (Suppl. 03) 34-39
• 4 Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52 (5) 611-622
• 5 Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24 (9) 1383-1388
• 6 Worm SW, Bower M, Reiss P , et al; D:A:D Study Group. Non-AIDS defining cancers in the D:A:D Study—time trends and predictors of survival: a cohort study. BMC Infect Dis 2013; 13: 471
• 7 Phelps RM, Smith DK, Heilig CM , et al; HER Study Group. Cancer incidence in women with or at risk for HIV. Int J Cancer 2001; 94 (5) 753-757
• 8 Kirk GD, Merlo C, O' Driscoll P , et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007; 45 (1) 103-110
• 9 Chaturvedi AK, Pfeiffer RM, Chang L, Goedert JJ, Biggar RJ, Engels EA. Elevated risk of lung cancer among people with AIDS. AIDS 2007; 21 (2) 207-213
• 10 Shiels MS, Cole SR, Mehta SH, Kirk GD. Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J Acquir Immune Defic Syndr 2010; 55 (4) 510-515
• 11 Sigel K, Wisnivesky J, Gordon K , et al. HIV as an independent risk factor for incident lung cancer. AIDS 2012; 26 (8) 1017-1025
• 12 Hessol NA, Seaberg EC, Preston-Martin S , et al; WIHS Collaborative Study Group. Cancer risk among participants in the women's interagency HIV study. J Acquir Immune Defic Syndr 2004; 36 (4) 978-985
• 13 Crothers K, Goulet JL, Rodriguez-Barradas MC , et al. Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans. AIDS Educ Prev 2009; 21 (3, Suppl): 40-53
• 14 Clifford GM, Lise M, Franceschi S , et al; Swiss HIV Cohort Study. Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer 2012; 106 (3) 447-452
• 15 Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR ; INSIGHT SMART Study Group. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health 2010; 100 (10) 1896-1903
• 16 Koshiol J, Rotunno M, Consonni D , et al. Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study. PLoS ONE 2009; 4 (10) e7380
• 17 Agustí A, Edwards LD, Rennard SI , et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 2012; 7 (5) e37483
• 18 Crothers K, Huang L, Goulet JL , et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med 2011; 183 (3) 388-395
• 19 Diaz PT, King MA, Pacht ER , et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000; 132 (5) 369-372
• 20 Twigg HL, Soliman DM, Day RB , et al. Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection. Am J Respir Crit Care Med 1999; 159 (5 Pt 1) 1439-1444
• 21 Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009; 360 (23) 2445-2454
• 22 Morris AM, Huang L, Bacchetti P , et al; The Pulmonary Complications of HIV Infection Study Group. Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons. Am J Respir Crit Care Med 2000; 162 (2 Pt 1): 612-616
• 23 Morris A, Alexander T, Radhi S , et al. Airway obstruction is increased in pneumocystis-colonized human immunodeficiency virus-infected outpatients. J Clin Microbiol 2009; 47 (11) 3773-3776
• 24 Christensen PJ, Preston AM, Ling T , et al. Pneumocystis murina infection and cigarette smoke exposure interact to cause increased organism burden, development of airspace enlargement, and pulmonary inflammation in mice. Infect Immun 2008; 76 (8) 3481-3490
• 25 Attia EF, Akgün KM, Wongtrakool C , et al. Increased risk of radiographic emphysema in HIV is associated with elevated soluble CD14 and nadir CD4. Chest 2014; 146 (6) 1543-1553
• 26 Crothers K, Sigel K, Wisnivesky J , et al. Inflammatory Biomarkers and CT-Detected Lung Nodules: Potential Implications for Lung Cancer Screening in HIV-Infected Patients. International Conference on Malignancies in AIDS and Other Immunodeficiencies. Bethesda, MD; 2013
• 27 Cho WC, Kwan CK, Yau S, So PP, Poon PC, Au JS. The role of inflammation in the pathogenesis of lung cancer. Expert Opin Ther Targets 2011; 15 (9) 1127-1137
• 28 Wu AH, Fontham ET, Reynolds P , et al. Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1995; 141 (11) 1023-1032
• 29 Liang HY, Li XL, Yu XS , et al. Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systematic review. Int J Cancer 2009; 125 (12) 2936-2944
• 30 Mayne ST, Buenconsejo J, Janerich DT. Previous lung disease and risk of lung cancer among men and women nonsmokers. Am J Epidemiol 1999; 149 (1) 13-20
• 31 Littman AJ, Thornquist MD, White E, Jackson LA, Goodman GE, Vaughan TL. Prior lung disease and risk of lung cancer in a large prospective study. Cancer Causes Control 2004; 15 (8) 819-827
• 32 Ramanakumar AV, Parent ME, Menzies D, Siemiatycki J. Risk of lung cancer following nonmalignant respiratory conditions: evidence from two case-control studies in Montreal, Canada. Lung Cancer 2006; 53 (1) 5-12
• 33 Shebl FM, Engels EA, Goedert JJ, Chaturvedi AK. Pulmonary infections and risk of lung cancer among persons with AIDS. J Acquir Immune Defic Syndr 2010; 55 (3) 375-379
• 34 Bordon J, Aliberti S, Fernandez-Botran R , et al. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. Int J Infect Dis 2013; 17 (2) e76-e83
• 35 Rubbo PA, Tuaillon E, Bolloré K , et al. The potential impact of CD4+ T cell activation and enhanced Th1/Th2 cytokine ratio on HIV-1 secretion in the lungs of individuals with advanced AIDS and active pulmonary infection. Clin Immunol 2011; 139 (2) 142-154
• 36 Dubrow R, Silverberg MJ, Park LS, Crothers K, Justice AC. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol 2012; 24 (5) 506-516
• 37 Yanik EL, Napravnik S, Cole SR , et al. Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence. AIDS 2014; 28 (7) 979-987
• 38 Silverberg MJ, Chao C, Leyden WA , et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev 2011; 20 (12) 2551-2559
• 39 Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D ; Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10 (12) 1152-1159
• 40 Reekie J, Kosa C, Engsig F , et al; EuroSIDA Study Group. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer 2010; 116 (22) 5306-5315
• 41 Kesselring A, Gras L, Smit C , et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2011; 52 (12) 1458-1465
• 42 Hleyhel M, Hleyhel M, Bouvier AM , et al; Cancer Risk Group of the French Hospital Database on HIV (FHDH-ANRS CO4). Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. AIDS 2014; 28 (14) 2109-2118
• 43 Sigel K, Crothers K, Gordon K , et al. CD4 Measures as Predictors of Lung Cancer Risk and Prognosis in HIV Infection. Conference on Retroviruses and Opportunistic Infections. Seattle, WA; 2015
• 44 Poirier MC, Olivero OA, Walker DM, Walker VE. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol 2004; 199 (2) 151-161
• 45 Vivanti A, Soheili TS, Cuccuini W , et al. Comparing genotoxic signatures in cord blood cells from neonates exposed in utero to zidovudine or tenofovir. AIDS 2015; 29 (11) 1319-1324
• 46 André-Schmutz I, Dal-Cortivo L, Six E , et al. Genotoxic signature in cord blood cells of newborns exposed in utero to a Zidovudine-based antiretroviral combination. J Infect Dis 2013; 208 (2) 235-243
• 47 Bruyand M, Le Marec F, Lavole A , et al. Protease inhibitors exposure is not related to lung cancer risk in HIV smoker patients: a nested case-control study. AIDS 2015; 29 (9) 1105-1109
• 48 Beltrán LM, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, García-Puig J, Moreno JA. Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus. Vasc Health Risk Manag 2015; 11: 35-48
• 49 Lu W, Mehraj V, Vyboh K, Cao W, Li T, Routy JP. CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients. J Int AIDS Soc 2015; 18: 20052
• 50 Borges AH, Silverberg MJ, Wentworth D , et al; INSIGHT SMART; ESPRIT; SILCAAT Study Groups. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS 2013; 27 (9) 1433-1441
• 51 Altavilla G, Caputo A, Lanfredi M, Piola C, Barbanti-Brodano G, Corallini A. Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene. Am J Pathol 2000; 157 (4) 1081-1089
• 52 Giagulli C, Marsico S, Magiera AK , et al. Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS ONE 2011; 6 (3) e17831
• 53 Kawabata S, Heredia A, Gills J, Redfield RR, Dennis PA, Bryant J. Impact of HIV on lung tumorigenesis in an animal model. AIDS 2015; 29 (5) 633-635
• 54 Hasegawa Y, Ando M, Kubo A , et al. Human papilloma virus in non-small cell lung cancer in never smokers: a systematic review of the literature. Lung Cancer 2014; 83 (1) 8-13
• 55 De Paoli P, Carbone A. Carcinogenic viruses and solid cancers without sufficient evidence of causal association. Int J Cancer 2013; 133 (7) 1517-1529
• 56 Brock MV, Hooker CM, Engels EA , et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 2006; 43 (1) 47-55
• 57 Vyzula R, Remick SC. Lung cancer in patients with HIV-infection. Lung Cancer 1996; 15 (3) 325-339
• 58 D'Jaen GA, Pantanowitz L, Bower M , et al. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer 2010; 11 (6) 396-404
• 59 Sigel K, Crothers K, Dubrow R , et al. Prognosis in HIV-infected patients with non-small cell lung cancer. Br J Cancer 2013; 109 (7) 1974-1980
• 60 Wistuba II, Behrens C, Milchgrub S , et al. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA 1998; 279 (19) 1554-1559
• 61 Okuma Y, Tanuma J, Kamiryo H , et al. A multi-institutional study of clinicopathological features and molecular epidemiology of epidermal growth factor receptor mutations in lung cancer patients living with human immunodeficiency virus infection. J Cancer Res Clin Oncol 2015; 141 (9) 1669-1678
• 62 Sigel K, Sigel C, Wisnivesky J , et al. Rates of Cancer Mutations in HIV Infected Non-Small Cell Lung Cancer Patients. 14th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies. Bethesda, MD; 2013
• 63 Howlader NNA, Krapcho M, Neyman N, , et al. In: Edwards BK. , ed. SEER Cancer Statistics Review 1975–2008. Bethesda, MD: National Cancer Institute; 2011
• 64 Tirelli U, Spina M, Sandri S , et al; The Italian Cooperative Group on AIDS and Tumors. Lung carcinoma in 36 patients with human immunodeficiency virus infection. Cancer 2000; 88 (3) 563-569
• 65 Biggar RJ, Engels EA, Ly S , et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005; 39 (3) 293-299
• 66 Suneja G, Shiels MS, Melville SK, Williams MA, Rengan R, Engels EA. Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS 2013; 27 (3) 459-468
• 67 Poluri A, Shah KG, Carew JF , et al. Hodgkin's disease of the head and neck in human immunodeficiency virus-infected patients. Am J Otolaryngol 2002; 23 (1) 12-16
• 68 Bourcier V, Winnock M, Ait Ahmed M , et al; ANRS CO13 Hepavih study group; ANRS CO12 Cirvir study group. Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clin Res Hepatol Gastroenterol 2012; 36 (3) 214-221
• 69 Rodrigues LK, Klencke BJ, Vin-Christian K , et al. Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol 2002; 138 (6) 765-770
• 70 Hooker CM, Meguid RA, Hulbert A , et al. Human immunodeficiency virus infection as a prognostic factor in surgical patients with non-small cell lung cancer. Ann Thorac Surg 2012; 93 (2) 405-412
• 71 Makinson A, Tenon JC, Eymard-Duvernay S , et al. Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study. J Thorac Oncol 2011; 6 (6) 1022-1029
• 72 Ferketich AK, Diaz P, Browning KK , et al. Safety of varenicline among smokers enrolled in the lung HIV study. Nicotine Tob Res 2013; 15 (1) 247-254
• 73 Lloyd-Richardson EE, Stanton CA, Papandonatos GD , et al. Motivation and patch treatment for HIV+ smokers: a randomized controlled trial. Addiction 2009; 104 (11) 1891-1900
• 74 Shuter J, Morales DA, Considine-Dunn SE, An LC, Stanton CA. Feasibility and preliminary efficacy of a web-based smoking cessation intervention for HIV-infected smokers: a randomized controlled trial. J Acquir Immune Defic Syndr 2014; 67 (1) 59-66
• 75 Jaklitsch MT, Jacobson FL, Austin JH , et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg 2012; 144 (1) 33-38
• 76 National Comprehensive Cancer Network Lung Cancer Screening Guidelines. Thorac Surg Clin 2015; 25 (2) 185-197
• 77 Bach PB, Mirkin JN, Oliver TK , et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012; 307 (22) 2418-2429
• 78 Nakagawa F, May M, Phillips A. Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis 2013; 26 (1) 17-25
• 79 Aberle DR, Adams AM, Berg CD , et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365 (5) 395-409
• 80 Crum-Cianflone N, Stepenosky J, Medina S, Wessman D, Krause D, Boswell G. Clinically significant incidental findings among human immunodeficiency virus-infected men during computed tomography for determination of coronary artery calcium. Am J Cardiol 2011; 107 (4) 633-637
• 81 Crothers K, Thompson BW, Burkhardt K , et al; Lung HIV Study. HIV-associated lung infections and complications in the era of combination antiretroviral therapy. Proc Am Thorac Soc 2011; 8 (3) 275-281
• 82 Cohen JV, Stern J, Henry D. Correlating age-at-diagnosis of lung cancer in the HIV/AIDS population (Abstract #437). 49th Infectious Diseases Society of America Conference. Boston; 2011
• 83 Diaz PT, Clanton TL, Pacht ER. Emphysema-like pulmonary disease associated with human immunodeficiency virus infection. Ann Intern Med 1992; 116 (2) 124-128
• 84 Kuhlman JE, Knowles MC, Fishman EK, Siegelman SS. Premature bullous pulmonary damage in AIDS: CT diagnosis. Radiology 1989; 173 (1) 23-26
• 85 Morris A, George MP, Crothers K , et al; Lung HIV Study. HIV and chronic obstructive pulmonary disease: is it worse and why?. Proc Am Thorac Soc 2011; 8 (3) 320-325
• 86 Petrache I, Diab K, Knox KS , et al. HIV associated pulmonary emphysema: a review of the literature and inquiry into its mechanism. Thorax 2008; 63 (5) 463-469
• 87 Wiener RS, Schwartz LM, Woloshin S, Welch HG. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med 2011; 155 (3) 137-144
• 88 Wu CC, Maher MM, Shepard JA. Complications of CT-guided percutaneous needle biopsy of the chest: prevention and management. AJR Am J Roentgenol 2011; 196 (6) W678-82
• 89 Black C, Bagust A, Boland A , et al. The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. Health Technol Assess 2006; 10 (3) iii-iv , ix–x, 1–90
• 90 Goulart BH, Bensink ME, Mummy DG, Ramsey SD. Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. J Natl Compr Canc Netw 2012; 10 (2) 267-275
• 91 Poghosyan H, Kennedy Sheldon L, Cooley ME. The impact of computed tomography screening for lung cancer on smoking behaviors: a teachable moment?. Cancer Nurs 2012; 35 (6) 446-475
• 92 Sigel K, Wisnivesky J, Shahrir S , et al. Findings in asymptomatic HIV-infected patients undergoing chest computed tomography testing: implications for lung cancer screening. AIDS 2014; 28 (7) 1007-1014
• 93 Clausen E, Wittman C, Gingo M , et al. Chest computed tomography findings in HIV-infected individuals in the era of antiretroviral therapy. PLoS ONE 2014; 9 (11) e112237
• 94 Hulbert A, Hooker CM, Keruly JC , et al. Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers. J Thorac Oncol 2014; 9 (6) 752-759
• 95 Makinson A, Eymard-Duvernay S, Raffi F , et al. High Frequency of Early Lung Cancer Diagnosis with Chest CT in HIV Infected Smokers. Conference on Retroviruses and Opportunistic Infections. Seattle, WA; 2015
• 96 International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92 (22) 1823-1830
• 97 Gramolelli S, Schulz TF. The role of Kaposi sarcoma-associated herpesvirus in the pathogenesis of Kaposi sarcoma. J Pathol 2015; 235 (2) 368-380
• 98 Shiels MS, Pfeiffer RM, Gail MH , et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011; 103 (9) 753-762
• 99 Palmieri C, Dhillon T, Thirlwell C , et al. Pulmonary Kaposi sarcoma in the era of highly active antiretroviral therapy. HIV Med 2006; 7 (5) 291-293
• 100 Pinzone MR, Berretta M, Cacopardo B, Nunnari G. Epstein-barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection. Semin Oncol 2015; 42 (2) 258-271
• 101 Leidner RS, Aboulafia DM. Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 2005; 19 (10) 635-644
• 102 Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med 2007; 357 (13) 1352-1353
• 103 Ensoli B, Stürzl M. Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. Cytokine Growth Factor Rev 1998; 9 (1) 63-83
• 104 Aka PV, Kemp TJ, Rabkin CS , et al. A multiplex panel of plasma markers of immunity and inflammation in classical Kaposi sarcoma. J Infect Dis 2015; 211 (2) 226-229
• 105 Foster CB, Lehrnbecher T, Samuels S , et al. An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood 2000; 96 (7) 2562-2567
• 106 Masiá M, Robledano C, Ortiz de la Tabla V , et al. Coinfection with human herpesvirus 8 is associated with persistent inflammation and immune activation in virologically suppressed HIV-infected patients. PLoS ONE 2014; 9 (8) e105442
• 107 Khalil AM, Carette MF, Cadranel JL, Mayaud CM, Bigot JM. Intrathoracic Kaposi's sarcoma. CT findings. Chest 1995; 108 (6) 1622-1626
• 108 Hoskote SS, Patel VP. Pulmonary Kaposi sarcoma in AIDS. Mayo Clin Proc 2012; 87 (10) e77
• 109 Hamm PG, Judson MA, Aranda CP. Diagnosis of pulmonary Kaposi's sarcoma with fiberoptic bronchoscopy and endobronchial biopsy. A report of five cases. Cancer 1987; 59 (4) 807-810
• 110 Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 2004; 22 (3) 399-402
• 111 Gbabe OF, Okwundu CI, Dedicoat M, Freeman EE. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults. Cochrane Database Syst Rev 2014; 8: CD003256
• 112 Ray P, Antoine M, Mary-Krause M , et al. AIDS-related primary pulmonary lymphoma. Am J Respir Crit Care Med 1998; 158 (4) 1221-1229
• 113 Bazot M, Cadranel J, Benayoun S, Tassart M, Bigot JM, Carette MF. Primary pulmonary AIDS-related lymphoma: radiographic and CT findings. Chest 1999; 116 (5) 1282-1286
• 114 Cadranel J, Wislez M, Antoine M. Primary pulmonary lymphoma. Eur Respir J 2002; 20 (3) 750-762
• 115 Starzl TE, Nalesnik MA, Porter KA , et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1 (8377) 583-587
• 116 Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA ; HIV/AIDS Cancer Match Study. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99 (12) 962-972
• 117 Cadranel J, Naccache J, Wislez M, Mayaud C. Pulmonary malignancies in the immunocompromised patient. Respiration 1999; 66 (4) 289-309
• 118 Marks MA, Rabkin CS, Engels EA , et al. Markers of microbial translocation and risk of AIDS-related lymphoma. AIDS 2013; 27 (3) 469-474
• 119 Dean M, Jacobson LP, McFarlane G , et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res 1999; 59 (15) 3561-3564
• 120 Rabkin CS, Yang Q, Goedert JJ, Nguyen G, Mitsuya H, Sei S. Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1-infected individuals. Blood 1999; 93 (6) 1838-1842
• 121 Spina M, Carbone A, Vaccher E , et al. Outcome in patients with non-Hodgkin lymphoma and with or without human immunodeficiency virus infection. Clin Infect Dis 2004; 38 (1) 142-144
• 122 Navarro JT, Lloveras N, Ribera JM, Oriol A, Mate JL, Feliu E. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica 2005; 90 (5) 704-706
• 123 Diamond C, Taylor TH, Im T, Anton-Culver H. Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma 2006; 47 (9) 1822-1829
• 124 Ribera JM, Oriol A, Morgades M , et al; PETHEMA, GELTAMO, GELCAB and GESIDA Groups. Safety and efficacy of cyclophosphamide, Adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol 2008; 140 (4) 411-419
• 125 Barta SK, Xue X, Wang D , et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood 2013; 122 (19) 3251-3262
• 126 Kaplan LD, Lee JY, Ambinder RF , et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005; 106 (5) 1538-1543
• 127 Spina M, Jaeger U, Sparano JA , et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005; 105 (5) 1891-1897
• 128 Cooksley N, Judge DJ, Brown J. Primary pulmonary Hodgkin's lymphoma and a review of the literature since 2006. BMJ Case Rep . 2014 Apr 7.
• 129 Barta SK, Samuel MS, Xue X , et al. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Ann Oncol 2015; 26 (5) 958-966
• 130 Massera F, Rocco G, Rossi G , et al. Pulmonary resection for lung cancer in HIV-positive patients with low (<200 lymphocytes/mm(3)) CD4(+) count. Lung Cancer 2000; 29 (2) 147-149
• 131 Bearz A, Vaccher E, Martellotta F , et al; Italian Cooperative Group on AIDS and Tumors. Lung cancer in HIV positive patients: the GICAT experience. Eur Rev Med Pharmacol Sci 2014; 18 (4) 500-508
• 132 Powles T, Thirwell C, Newsom-Davis T , et al. Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART?. Br J Cancer 2003; 89 (3) 457-459
• 133 Lavolé A, Chouaïd C, Baudrin L , et al. Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. Lung Cancer 2009; 65 (3) 345-350